Our Business Partner
Actoverco Pharmaceutical Factories 1 and 2
Actoverco Biotech factory
The biotechnology site, with more than 3,000 m2 of total infrastructure, including 2,000 m2 of clean rooms and a production capacity of more than 40 million vials and pre-filled syringes, was launched in 2014 with the aim of producing recombinant drugs such as MS drugs and monoclonal antibodies.
At the beginning of 2018, Phase 2 of biotechnology factory started its activities with an infrastructure of about 5000 m2, including 3000 m2 of clean rooms. In this project, single-use bioreactor technology has been used for the first time in Iran and the Middle East.